Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BW-00112
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $5,360.0 million
Deal Type : Collaboration
Argo Announces License and Option Agreements with Novartis for Novel Molecules
Details : An option granted to Novartis to license ex-China rights to two discovery-stage molecules for the treatment of sHTG and mixed dyslipidemia and a right of first negotiation to BW-00112 (ANGPTL3).
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : $160.0 million
September 03, 2025
Lead Product(s) : BW-00112
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $5,360.0 million
Deal Type : Collaboration
Lead Product(s) : BW-20507
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Study of BW-20507 with PEG-IFNα in Hepatitis B
Details : BW-20507 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Hepatitis B, Chronic.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 22, 2025
Lead Product(s) : BW-20507
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BW-40202
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Safety and Effects of the Investigational Drug BW-40202 in Healthy Volunteers
Details : BW-40202 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 08, 2025
Lead Product(s) : BW-40202
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BW-20805
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 2 in Adult Subjects With Hereditary Angioedema
Details : BW-20805 is a Oligonucleotide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Angioedemas, Hereditary.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 26, 2025
Lead Product(s) : BW-20805
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BW-00112
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study in Patients With Mixed Dyslipidemia
Details : BW-00112 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dyslipidemias.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 11, 2024
Lead Product(s) : BW-00112
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BW-02
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $4,165.0 million
Deal Type : Licensing Agreement
Shanghai Argo Announces RNAi Licenses and Collaborations with Novartis
Details : Argo has granted Novartis global licenses to develop and commercialize a Phase 1 program, allowing Novartis to select targets and drive discovery and optimization of lead candidates.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : $185.0 million
January 07, 2024
Lead Product(s) : BW-02
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $4,165.0 million
Deal Type : Licensing Agreement